Pleiotropic effects of statins: Moving beyond cholesterol control

Current Atherosclerosis Reports

Volumn 7, Issue 1, 2005, Pages 34-39

  Garcia, Paul J ^a  

^a University of North Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; COMPACTIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVALONIC ACID; MEVINOLIN; NITRIC OXIDE; PRAVASTATIN; PROTEIN P21; TISSUE INHIBITOR OF METALLOPROTEINASE;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EVIDENCE BASED MEDICINE; HEART MUSCLE ISCHEMIA; HUMAN; INFECTION; INFLAMMATION; ONCOLOGY; PRESCRIPTION; PRIMARY PREVENTION; REVIEW; RHEUMATOLOGY; RISK REDUCTION; SECONDARY PREVENTION; VASCULAR DISEASE;

EID: 15544378130     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-005-0073-6     Document Type: Review

References (59)

1. Endo A, Kuroda M, Tsujita Y: ML-236A, ML-236B and ML-236C, new inhibitors of cholesterolgenesis produced by Penicillium citrinum. J Antibiot 1976, 29:1346-1348.
2. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389.
3. Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301-1307.
4. Sacks FM, Pfeffer MA, Lemuel A: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001-1009.
5. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357.
6. Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA 1998, 279:1615-1622.
7. Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996, 348:1079-1082.
8. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 1990, 343:425-430.
9. Bellosta S, Ferri N, Bernini F, et al.: Non-lipid-related effects of statins. Ann Med 2000, 32: 64-176.
10. Schonbeck U, Libby P: Inflammation, immunity, and HMG-CoA reductase inhibitors. Circulation 2004, 109:II-18-II-26.
11. Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med 1999, 340:115-126.
12. Cayatte AJ, Palacino JJ, Horten K, et al.: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler Thromb 1994, 14:753-759.
13. Hamon M, Vallet B, Bauters C, et al.: Long-term oral administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury. Circulation 1994, 90:1357-1362.
14. O'Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-CoA reductase inhibitor, improves endothelial function within 1 month. Circulation 1997, 95:1126-1131.
15. Newby DE, Wright RA, Labinjoh C, et al.: Endothelial dysfunction, impaired endogenous fibrinolysis, and cigarette smoking. Circulation 1999, 99:1411-1415.
16. Panza JA, Garcia CE, Kilcoyne CM, et al.: Impaired endothelium-dependent vasodilation in patients with essential hypertension: Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway. Circulation 1995, 91: 732-1738.
17. Kawano H, Motoyama T, Hirashima O, et al.: Hyperglycemia rapidly supresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 1999, 34: 46-154.
18. Liao JK, Bettmann MA, Sandor T, et al.: Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res 1991, 68:1027-1034.
19. Radomski MW, Palmer RM, Moncada S: An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci U S A 1990, 87:5193-5197.
20. Garg UC, Hassid A: Nitric oxide-generating vasodilators and 8-bromocyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest 1989, 83:1774-1777.
21. Kubes P, Suzuki M, Granger DN: Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci U S A 1991, 88:4651-4655.
22. Brown D, London E: Structure and function of sphingolipid and cholesterol-rich membrane rafts. J Biol Chem 2000, 275: 7221-17224.
23. Feron O, Saldana F. Michel JB, et al.: The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 1998, 273:3125-3128.
24. Tamai O, Matsuoka H, Itabe H, et al.: Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
25. Harris MB, Blackstone MA, Sood SG, et al.: Acute activation and phosphorylation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Am J Physiol Heart Circ Physiol 2004, 287:H560-H566.
26. Takemoto M, Liao, J: Pleiotropic effects of 3-hydroxy-3-Methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001, 21:1712-1719.
27. Feron O, Dessy C, Desager JP, et al.: Hydroxy-methylglutaryl-coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001, 103:113-118.
28. Vergnani L, Hatrik S, Ricci F, et al.: Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability. Circulation 2000, 101:1261-1266.
29. Rikitake Y, Kawashima S, Takeshita S, et al.: Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis 2001, 154:87-96.
30. Ohara Y, Peterson TE, Harrison DG: Hypercholseterolemia increases endothelial superoxide anion production. J Clin Invest 1993, 91:2546-2551.
31. Aikawa M, Voglic SJ, Sugiyama S, et al.: Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 1999, 100:1215-1222.
32. Ridker PM, Rifai N, Rose L, et al.: Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
33. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
34. Weber C, Erl W, Weber KS, et al.: HMG-CoA recuctase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes; to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypecholesterolemia. J Am Coll Cardiol 1997, 30:1212-1217.
35. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al.: Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001, 7:687-692.
36. Martinez-Gonzalez J, Alfon J, Berrozpe M, et al.: HMG-CoA reductase inhibitors reduce vascular monocyte chemotactic protein- 1 expression in early lesions from hypercholesterolic swine independently of their effect on plasma cholesterol levels. Atherosclerosis 2001, 159:27-33.
37. Guijarro C, Blanco-Colio LM, Ortego M, et al.: 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998, 83:490-500.
38. Isner J: Apoptosis in human atherosclerosis and restenosis. Circulation 1995, 91:2703-2711.
39. Weis M, Heeschen C, Glassford A, et al.: Statins have biphasic effects on angiogenesis. Circulation 2002, 105: 39-745.
40. von der Thusen JH, van Vlijmen BJ, Hoeben RC, et al.: Induction of atherosclerotic plaque rupture in apoliproprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 2002, 105:2064-2070.
41. Crisby M, Nordin-Fredriksson C, Shah PK, et al.: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001, 103:926-933.
42. Stoneman V, Bennett M: Role of apoptosis in atherosclerosis and its therapeutic implications. Clin Sci 2004, 86:1-23.
43. Aikawa M, Rabkin E, Sugiyama S, et al.: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation 2001, 103:276-283.
44. Essig M, Nguyen G, Prie D, et al.: 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998, 83: 83-690.
45. Bourcier T, Libby P: HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:556-562.
46. Vaughan CJ, Gotto AM Jr, Basson CT: The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000, 35:1-10.
47. Degraeve F, Bolla M, Blaie S, et al.: Modulation of COX-2 expression by statins in human aortic smooth muscle cells. Involvement of geranylgeranylated proteins. J Biol Chem 2001, 276:46849-46855.
48. Almog Y, Shefer A, Novack V, et al.: Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation 2004, 110:880-885.
49. Node K, Fujita M, Kitakaze M, et al.: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003, 108: 39-843.
50. Kobashigawa J, Katznelson S, Laks H, et al.: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995, 333:621-627.
51. Bennett MR: Apoptosis of vascular smooth muscle cells in vascular remodeling and atherosclerotic plaque rupture. Cardiovasc Res 1999, 41:361-368.
52. Kureishi Y, Luo Z, Shiojima I, et al.: The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nature Med 2000, 6:1004- 1010.
53. Sata M, Nishimatsu H, Osuga J, et al.: Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 2004, 43: 214-1220.
54. Bjere LM, LeLorier J: Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001, 110:716-723.
55. Wong WW, Dimitroulakos J, Minden MD, et al.: HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002, 16: 08-519.
56. Poynter J: HMG CoA reductase inhibitors and the risk of colorectal cancer. Presented at the 2004 American Society of Clinical Oncology. New Orleans, June 5-8, 2004.
57. Vollmer T, Lyndon K, Durkalski V, et al.: Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004, 363:1607-1608.
58. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, et al.: Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003, 12:607-611.
59. Waldman A, Kritharides L: The pleiotropic effects of HMG-CoA reductase inhibitors: their role in osteoporosis and dementia. Drugs 2003, 63:139-152.